GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Shares Outstanding (EOP)

89bio (ETNB) Shares Outstanding (EOP) : 95.20 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is 89bio Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. 89bio's shares outstanding for the quarter that ended in Mar. 2024 was 95.20 Mil.

89bio's quarterly shares outstanding increased from Dec. 2023 (93.27 Mil) to Mar. 2024 (95.20 Mil). It means 89bio issued new shares from Dec. 2023 to Mar. 2024 .

89bio's annual shares outstanding increased from Dec. 2022 (50.56 Mil) to Dec. 2023 (93.27 Mil). It means 89bio issued new shares from Dec. 2022 to Dec. 2023 .


89bio Shares Outstanding (EOP) Historical Data

The historical data trend for 89bio's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Shares Outstanding (EOP) Chart

89bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 13.79 19.93 20.32 50.56 93.27

89bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.87 75.47 75.64 93.27 95.20

Competitive Comparison of 89bio's Shares Outstanding (EOP)

For the Biotechnology subindustry, 89bio's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


89bio's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 89bio's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where 89bio's Shares Outstanding (EOP) falls into.



89bio Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


89bio  (NAS:ETNB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


89bio Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of 89bio's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


89bio (ETNB) Business Description

Industry
Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
Kathleen Laporte director
Rohan Palekar director, officer: Chief Executive Officer 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Atkinson Edward Morrow Iii director C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Quoc Le-nguyen officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ryan Martins officer: Chief Financial Officer 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd officer: See Remarks 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg director, 10 percent owner 100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz director, 10 percent owner 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc 10 percent owner 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026

89bio (ETNB) Headlines

From GuruFocus

89bio Provides Business Update and Outlook for 2023

By Stock market mentor Stock market mentor 01-04-2023

89bio to Participate in the SVB Securities Global Biopharma Conference

By Stock market mentor Stock market mentor 02-08-2023